哪里想瘦打哪里！FDA批准Kythera注射药物香港交易所在即

你才双下巴，你继父都双下巴！是非爱美心人皆有之。如果说赘肉是每一个愿意具备极致身材的“妹纸”或“汉纸”的厉，那么一个笑点十足的双下巴却是是这些人的生死仇敌了。每一分钟，多国都有人为自己的一张大饼脸而感到无常，虽然具备一个肉感十足的双下巴捏上去是挺有肉感的，但是还是有很多人的扎实使其无法受压一个双下巴之重。您可千万别笑，这甚至已经催生单单一个相当可观的市场需求。根据美国表皮外科手术联合会的清查研究推测，68%的美国人对自己的双下巴暗示了“灰心”之情。而有鉴于，早先Kythera子公司向FDA提交了其专门铲除双下巴的瘦身口服式制剂ATX-101。这种制剂完成了许多“胖纸”梦寐以求的功能，哪里想瘦打哪里，却是是定点瘦身。不要以为这种近乎任性的制剂只是一个幽默，在FDA下属的表皮和眼科制剂处长会的无记名投票中会，研究专家可是以17：0的超高票一致拥护其港交所。确实是因为这些研究专家中会也有很多饱受双下巴之苦吧。FDA也将原先于来年的5同年13日之前对其作单单最后提议。如果一切顺利的话，Kythera子公司原先于来年当年将该产品港交所，分析人士预计这一制剂的交易额将超过3亿美元之多。随着瘦身制剂市场需求的愈加增高，Kythera子公司却是是下了一步好棋。子公司于月内以8400万美元的市价从其前合作伙伴拜耳手中会归还了这种制剂的全部基本权利。而Kythera子公司也愿意依此为日后在瘦身制剂市场需求中会攻城拔寨。就在上个同年，Kythera子公司和Actelion子公司达成价值2700万美元的合作协议，开发设计一种失败过的抗炎症制剂，而这种制剂被普遍认为有可能开发单单一种疗程表皮病的制剂。详尽英文媒体报道：Kythera ($KYTH) won the unanimous support of an FDA advisory panel for its fat-busting injection, rolling toward approval with a first-of-its-kind treatment.The agency's independent Dermatologic and Ophthalmic Drugs Advisory Committee voted 17-0 that the drug's benefits outweighed its risks for patients looking to reduce submental fat, or double chin. The FDA is not required to follow its panels' votes, though it most commonly does, and the agency has promised to make a final decision on the injection by May 13. If all goes according to plan, Kythera plans to launch the drug, ATX-101, in the second half of this year.The biotech's shares he more than tripled since it pulled off a $73 million IPO in 2012, rising steadily as investors bet ATX-101 can carve out a space on the aesthetic market and potentially lure a Big Pharma acquirer. Kythera is pitching the injection as a much-needed nonsurgical option for double chin reduction, citing an American Society for Dermatologic Surgery survey that estimates 68% of Americans are "bothered" by submental fat.Kythera regained full rights to ATX-101's potential last year, orchestrating an $84 million deal to buy out ex-partner Bayer. And the drug, a synthetic version of the fat-blasting deoxycholic acid, could bring in more than $300 million a year once approved, Leerink yst Seamus Fernandez has said."This milestone demonstrates our commitment to developing first-in-class aesthetic products through a focus on scientific rigor and innovation," Kythera CEO Keith Leonard said in a statement. "At Kythera, we remain focused on investing in novel treatments that will allow aesthetic physicians to better meet the needs of their patients."Kythera is also focused on raising some cash now that it has a likely approval ahead. The biotech filed for a $125 million offering as soon as the market closed on Monday. Its share price was down several points at the end of the day.Beyond its top prospect, Kythera is working to build out a pipeline of aesthetic medicines. Last month, the California biotech signed a $27 million deal with Actelion ($ATLN) to get its hands on a once-failed anti-inflammatory medicine that could he a future as a treatment for hair loss.